Yorvipath

(Palopegteriparatide)

PreclinicalPeptide

Ascendis Pharma

Yorvipath is one of 19 small molecule programs targeting Hypoparathyroidism. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

HypoparathyroidismActive, not recruiting

HypoparathyroidismPreclinical

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Hypoparathyroidism

#DrugCompanyPhaseTrials

Theo-Dur

Pfizer

Approved

3 2

Calciferol

Alnylam Pharmaceuticals

Approved

—3

Rocaltrol

Alnylam Pharmaceuticals

Klor-Con

1 5

One-Alpha

Roche

Phase 2

1 6

Forteo

AAlmaject

Phase 2

2 7

Calcium Citrate

CCampus Bio-Medico University

Approved

1 8

Tums

Otsuka

Phase 2

1 9

Rhpth

Takeda

Phase 3

5 10

Transcon Hgh

VVisen Pharmaceuticals (Shanghai) Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Not yet recruiting

Breast

NCT07264634

Q1 2036

Recruiting

Pregnancy

NCT07345494

Clinical

Trials by Indication[1]

Breast1 trial

A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

Not yet recruiting·AAscendis Pharma A/S··NCT07264634·10 enrolled

Pregnancy1 trial

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

Recruiting·AAscendis Pharma A/S··NCT07345494·50 enrolled

Hypoparathyroidism1 trial

Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism

Approved for marketing·AAscendis Pharma Bone Diseases A/S··NCT05654701

Regulatory

FDA Approval Timeline[4]

Aug 9, 2024

YORVIPATH

NDA NDA216490

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Palopegteriparatide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Palopegteriparatide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Palopegteriparatide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA216490). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Yorvipath. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Ascendis Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Preclinical[1]
Company: Ascendis Pharma

Patent Landscape[5]

Patent Cliff

Apr 30, 2031

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8906847Apr 30, 2031

12295989Sep 28, 2037

11857603Sep 28, 2037

11590207Sep 28, 2037

11918628Sep 28, 2037

4 more patents

12453778Sep 28, 2037

11890326Sep 28, 2037

11759504Sep 28, 2037

12403182Nov 12, 2042

Yorvipath

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q1 2036

Trials by Indication[1]

Breast1 trial

Pregnancy1 trial

Hypoparathyroidism1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News